MK-0472
- Generic Name
- MK-0472
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Phase 1
Recruiting
- Conditions
- Metastatic Solid TumorsAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 178
- Registration Number
- NCT05853367
- Locations
- 🇨🇱
Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703), Santiago, Region M. De Santiago, Chile
🇵🇱Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0401), Warszawa, Mazowieckie, Poland
🇺🇸Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath